Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

University of Toronto

$55,300.00

Biological effects of oxygen activation

EF 2012-13

Résumé
Most living organisms thrive on oxygen to obtain energy from glucose needed to sustain life. Unfortunately reactive oxygen species (ROS) formation are by-products of oxygen metabolism which can be lethal to cells and have been linked to age associated diseases e.g cardiovascular, neurodegenerative diseases, and rheumatoid arthritis. Also of concern are endogenous reactive carbonyl species (RCS), by-products of glucose and fat metabolism. RCS can carbonylate essential proteins and/or nucleic acids thereby injuring cells which have also been linked to diseases, particularly diabetic complications and cardiovascular disease. Carbonyl by-products typically appear as either 1) unsaturated carbonyls formed from the decomposition products of lipid oxidation, e.g acrolein or 2) dicarbonyl species e.g glyoxal and methylglyoxal, formed from glucose by glycolysis or 3) acrolein or chloroacetaldehyde formed by the metabolism of cyclophosphamide or ifosfamide anticancer drugs. Recently we have discovered that RCS markedly increases ROS toxicity and are researching the molecular mechanisms involved. Others have also shown that minimal inflammation associated with oxidative stress increases RCS hepatotoxicity in vivo. We postulate that inflammatory cells increase RCS toxicity by forming ROS. Inflammatory cells cause oxidative stress in tissues largely because of an NADPH oxidase enzyme that forms ROS. We will use an oxidase inhibitor to prevent RCS induced tissue toxicity caused by the above anticancer drugs. The molecular mechanisms for the different susceptibility of normal cells versus tumor cells to ROS or RCS or ROS together with RCS will be investigated. The proposed research involves identifying target proteins and metabolising enzymes modulating the toxicity pathway. A novel application of QSAR will be used to determine why some dicarbonyls are toxic whereas others are not. As well, QSAR will identify the structural basis for dicarbonyl toxicities in different tissues using inhibitors of ROS/RCS detoxifying enzymes. It is hoped that this approach will lead to the development of novel QSAR techniques for comparing molecular toxicity mechanisms associated with ROS and RCS formation.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
3783-2008
Name nom
OBrien, PeterJohn
Department département
Pharmacy, Leslie Dan Faculty of
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2008
Award amount
55300
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
32
Committee name en
Cell Biology
Committee name fr
Biologie cellulaire
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
5100
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Cell biology
Research subject fr
Biologie cellulaire
Partie
5
Nb partie
5
Application title
Biological effects of oxygen activation
Keyword
NSERC
Application summary
Most living organisms thrive on oxygen to obtain energy from glucose needed to sustain life. Unfortunately reactive oxygen species (ROS) formation are by-products of oxygen metabolism which can be lethal to cells and have been linked to age associated diseases e.g cardiovascular, neurodegenerative diseases, and rheumatoid arthritis. Also of concern are endogenous reactive carbonyl species (RCS), by-products of glucose and fat metabolism. RCS can carbonylate essential proteins and/or nucleic acids thereby injuring cells which have also been linked to diseases, particularly diabetic complications and cardiovascular disease. Carbonyl by-products typically appear as either 1) unsaturated carbonyls formed from the decomposition products of lipid oxidation, e.g acrolein or 2) dicarbonyl species e.g glyoxal and methylglyoxal, formed from glucose by glycolysis or 3) acrolein or chloroacetaldehyde formed by the metabolism of cyclophosphamide or ifosfamide anticancer drugs. Recently we have discovered that RCS markedly increases ROS toxicity and are researching the molecular mechanisms involved. Others have also shown that minimal inflammation associated with oxidative stress increases RCS hepatotoxicity in vivo. We postulate that inflammatory cells increase RCS toxicity by forming ROS. Inflammatory cells cause oxidative stress in tissues largely because of an NADPH oxidase enzyme that forms ROS. We will use an oxidase inhibitor to prevent RCS induced tissue toxicity caused by the above anticancer drugs. The molecular mechanisms for the different susceptibility of normal cells versus tumor cells to ROS or RCS or ROS together with RCS will be investigated. The proposed research involves identifying target proteins and metabolising enzymes modulating the toxicity pathway. A novel application of QSAR will be used to determine why some dicarbonyls are toxic whereas others are not. As well, QSAR will identify the structural basis for dicarbonyl toxicities in different tissues using inhibitors of ROS/RCS detoxifying enzymes. It is hoped that this approach will lead to the development of novel QSAR techniques for comparing molecular toxicity mechanisms associated with ROS and RCS formation.